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Generation of lung organoids from human
pluripotent stem cells in vitro
Alyssa J. Miller1, Briana R. Dye2, Daysha Ferrer-Torres3, David R. Hill3, Arend W. Overeem4,
Lonnie D. Shea2 and Jason R. Spence 1,2,3,5,6*
The lung epithelium is derived from the endodermal germ layer, which undergoes a complex series of
endoderm–mesoderm-mediated signaling events to generate the ﬁnal arborized network of conducting airways (bronchi,
bronchioles) and gas-exchanging units (alveoli). These stages include endoderm induction, anterior–posterior and
dorsal–ventral patterning, lung speciﬁcation, lung budding, branching morphogenesis, and, ﬁnally, maturation. Here we
describe a protocol that recapitulates several of these milestones in order to differentiate human pluripotent stem cells
(hPSCs) into ventral–anterior foregut spheroids and further into two distinct types of organoids: human lung organoids
and bud tip progenitor organoids. The resulting human lung organoids possess cell types and structures that resemble the
bronchi/bronchioles of the developing human airway surrounded by lung mesenchyme and cells expressing alveolar-cell
markers. The bud tip progenitor organoids possess a population of highly proliferative multipotent cells with in vitro
multilineage differentiation potential and in vivo engraftment potential. Human lung organoids can be generated from
hPSCs in 50–85 d, and bud tip progenitor organoids can be generated in 22 d. The two hPSC-derived models presented
here have been benchmarked with human fetal tissue and found to be representative of human fetal-like tissue. The bud
tip progenitor organoids are thus ideal for exploring epithelial fate decisions, while the human lung organoids can be used
to model epithelial–mesenchymal cross-talk during human lung development. In addition to their applications in
developmental biology, human lung organoids and bud tip progenitor organoids may be implemented in regenerative
medicine, tissue engineering, and pharmaceutical safety and efﬁcacy testing.
Introduction
Development of the protocol
During development, the endodermal germ layer gives rise to the lining of the gut tube, which is
patterned along the anterior–posterior axis of the embryo into distinct morphological and molecular
domains1. The lung is speciﬁed in the ventral–anterior foregut endoderm region of the gut tube, and
development begins as two primordial lung buds emerge from this region. The lung buds possess a
population of multipotent epithelial progenitors at the tips (‘bud tip progenitors’) and are surrounded
by mesenchyme. As the lung grows, the epithelium undergoes repeated rounds of bifurcation in a
process known as branching morphogenesis, in order to establish the arborized architecture of the
adult lung. During the branching process, bud tip progenitors are maintained, continuously pro-
liferate, and give rise to all lung epithelial cell types. Early in development, branching establishes the
network of tubes that will conduct air (bronchi, bronchioles). Later during development, when the
branching program is completed, bud tip progenitors that remain at the end of the airways give rise to
alveolar epithelial cells2,3, as conﬁrmed by lineage tracing experiments in mice4.
Several studies have demonstrated that the recapitulation of key stages of embryonic development
through a series of steps in vitro, known as directed differentiation, is an effective method to generate
cell and tissue lineages of interest from hPSCs. Directed differentiation has been used to generate 3D
mid- and hindgut spheroids that give rise to small and large human intestinal organoids5–8, as well as
to generate 2D monolayers of ventral foregut cells and lung epithelial cell types9–15. Here we describe
protocols based on published work for the generation of 3D ventral–anterior foregut spheroids from
hPSCs15,16 and the differentiation of foregut spheroids into two distinct types of lung organoids:
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human lung organoids15 and bud tip progenitor organoids17 (Fig. 1). Human lung organoids are
generated if foregut spheroids are cultured with high levels of FGF10 and 1% FBS, and possess
airway-like epithelium surrounded by a diffuse network of mesenchymal cells and epithelial cells that
express alveolar-cell-type markers. The transcriptional proﬁle of these organoids is highly similar to
that of fetal lung. The presence of mesenchyme and organized airway structures is a strength of this
system, making it ideal for studies of mesenchymal epithelial cross-talk during fetal lung develop-
ment. Bud tip progenitor organoids are generated when foregut spheroids are cultured in a serum-
free environment with FGF7, CHIR-99021, and all-trans retinoic acid (ATRA). After 22 d in culture,
bud tip progenitor organoids contain a highly enriched and proliferative population of SOX2+-
SOX9+ID2+NKX2.1+ cells that are transcriptionally similar to human fetal bud tip progenitors.
These cells can be expanded in culture for more than 16 weeks. Given that bud tip progenitors are a
precursor cell to all epithelial cell types during development, bud tip progenitor organoids are
uniquely suited for studying mechanisms involved in epithelial cell fate decisions in the developing
human lung.
Overview of the experimental design
The generation of ventral–anterior foregut spheroids takes ~10 d. Subsequent differentiation into
human lung organoids takes 50–85 d, and differentiation into bud tip progenitor organoids takes ~22 d
(Fig. 1). The protocol begins with hPSCs grown in a monolayer, and differentiation is directed through
several stages, including deﬁnitive endoderm (4 d) and ventral–anterior foregut spheroids (5–6 d). Cells
begin as 2D monolayers of undifferentiated hPSCs, and during the speciﬁcation into ventral–anterior
foregut tissue, cells self-assemble into small clusters called spheroids and form free-ﬂoating structures
that detach from the cell monolayer. Foregut spheroids are then encapsulated in a 3D extracellular
matrix or synthetic hydrogel18 and are overlaid with speciﬁc growth factors and small molecules to
generate either human lung organoids (50–85 d)15 or bud tip progenitor organoids (22 d)17.
Foregut spheroids are differentiated in serum-free media. If subsequently embedded in a droplet of
Matrigel and grown in high levels of FGF10 and 1% (vol/vol) FBS, they give rise to human lung
organoids, which form airway-like structures and cell types surrounded by mesenchymal populations.
Further, some cells that express AECI and AECII markers are present in the organoids. These
organoids contain optimal airway-like tissue at 50–85 d of culture, but airway-like tissue has been
observed in organoids cultured for more than 100 d.
In contrast, foregut spheroids embedded in Matrigel and grown in serum-free medium containing
FGF7, CHIR-99021 and ATRA give rise to bud tip progenitor organoids, which are composed of
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Fig. 1 | Schematic of protocol and timeline. hPSCs in a monolayer are directed to endoderm and then anterior foregut endoderm over the course of
9–10 d. Foregut spheroids self-aggregate and lift away from the monolayer to ﬂoat in the media. These spheroids are then cultured in a 3D Matrigel
droplet, where they can be directed to become airway-like human lung organoids or bud tip progenitor organoids.
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SOX9+SOX2+ bud-tip-progenitor-like cells and have a transcriptome similar to that of bud tip
progenitors found in native human fetal lung during branching morphogenesis. If left unperturbed in
Matrigel droplets for several weeks, spheroids treated with FGF7, CHIR-99021 and ATRA will form
patterned branch-like structures with interior regions that express proximal airway markers, and
distal bud tip regions. Bud tip progenitors are highly proliferative and can be easily needle-passaged
for expansion/enrichment of progenitor populations. Bud tip progenitor organoids can be serially
passaged every 2 weeks and maintain a relatively uniform multipotent population of progenitor cells
in vitro. Manipulation of the in vitro growth factor milieu can promote the differentiation of bud tip
progenitor cells into differentiated lung epithelial cells that express both airway/bronchiolar cell
markers and alveolar cell markers17.
Experimental design
A schematic of the protocol is shown in Fig. 1. The ﬁrst 9 d of the protocol are the same for both types
of organoids described here: hPSCs are ﬁrst directed to deﬁnitive endoderm with activin A, then
directed to anterior foregut endoderm via inhibition of transforming growth factor β (TGF-β) and
bone morphogenic protein (BMP) signaling by SB-431542 and NOGGIN, respectively, in addition to
simultaneous activation of the WNT (CHIR-99021), Hedgehog (SAG) and ﬁbroblast growth factor 4
(FGF4) pathways. Foregut spheroids will self-assemble and can be transferred into a droplet of
Matrigel. After plating in Matrigel, differentiation into different lung lineages is controlled by the
growth factor signaling milieu (Fig. 1). Treatment of foregut spheroids with serum-free media
containing FGF7, CHIR-99021 and ATRA will result in bud tip progenitor organoids that possess
bud tip progenitors after 14 d in culture. This population can be easily expanded and maintained by
needle passaging, or, if left unpassaged, will give rise to lung epithelial structures with proximal–distal
patterning and a population of bud tip progenitors at budded tips after ~40 d in culture. Conversely,
treatment of foregut spheroids with 1% FBS and a high concentration of FGF10 for ~50 d will result
in human lung organoids that contain fetal airway-like structures with surrounding lung mesench-
yme and alveolar-progenitor-like cells. Speciﬁc mRNA and protein markers identiﬁed from human
lung development are used to determine whether cells have differentiated as expected.
Application of the method
The generation of self-aggregating foregut spheroids from hPSCs is the ﬁrst step in this protocol for
either type of organoid (Fig. 1). Depending on the signaling milieu applied to foregut spheroids, the
researcher can grow foregut spheroids that will give rise either to human lung organoids or to bud tip
progenitor organoids. Human lung organoids and bud tip progenitor organoids have been compared
to both human adult lung and fetal lung, and possess cells that are highly similar to the developing
human lung. Therefore, both systems are ideal for studying developmental biology and tissue
engineering.
Human lung organoids
These contain airway-like structures surrounded by lung mesenchymal cells and cells that stain
positive for AECI and AECII markers. Bulk RNA-seq analysis shows that these organoids are more
similar to native human fetal lung than to adult lung15. Because of the presence of mesenchyme,
airway structures and immature alveolar-like epithelial cells, human lung organoids are ideal for
studying mesenchymal–epithelial interactions during human lung development and for modeling
human fetal lung malformations using patient-speciﬁc cell lines or mutations. For example, our
ongoing work with these organoids is focused on epithelial mesenchymal cross-talk during pul-
monary ﬁbrosis, and on congenital malformations19 related to Wnt signaling (data not shown).
Human lung organoids can be microinjected20,21 with drugs or bacteria for investigation of their
effects in the context of development or disease (Fig. 2a), transplanted onto a bioengineered scaffold
to form mature airway structures and cell types (Fig. 2b–d), or seeded onto a decellularized lung
scaffold to generate mature airway cell types (Fig. 2e). These organoids are ideal for use after ~50–85
d in culture but are long-lived and stable in vitro, so experiments that last several weeks can easily be
carried out. Owing to these unique features, the human lung organoid model is ideal for studies of
epithelial–mesenchymal interactions during lung development, including maturation of alveolar cell
types, and may be ideal for modeling infections common to the immature lung, such as respiratory
syncytial virus.
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Bud tip progenitor organoids
These can be generated from hPSCs in 22 d (ref. 17). By 22 d, organoids contain a highly enriched
population of epithelial bud tip progenitor cells that are similar to bud tip progenitors residing at the
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expression and functional characterization. These cells are ideally suited for research on the
mechanisms of epithelial cell fate decisions in the developing lung, as bud tip progenitors are obligate
precursors to all lung epithelial cell types. Our work has shown that bud tip progenitor organoids
have multilineage potential in vitro, where they can give rise to airway-like and alveolar-like cells
(Fig. 2g,h), and ongoing studies in our laboratory have used this model system to study lineage
decisions, as bud tip progenitors give rise to multiple epithelial cell lineages (data not shown). We
speculate that this model may also be useful as a predictive preclinical model for many human lung
diseases22,23, or for testing pharmaceutical safety during pregnancy24. Because they are highly
expandable, bud tip progenitor organoids can be expanded to accommodate large screens to test
pharmaceuticals for potential effects on proliferation, apoptosis, metabolic function and changes in
lineage decisions. Large, easily identiﬁable lumens within these organoids allow drugs or pathogens to
be delivered by microinjection20,21 or in the surrounding medium (Fig. 2f). One unique feature of
cells derived from bud tip progenitor organoids is their ability to successfully engraft, proliferate and
repopulate differentiated airway cells in the injured mouse airway17. Thus, the high expandability and
multilineage potential of these organoids might make them suitable for cell-based regenerative
medicine applications, such as reseeding damaged airway epithelium in vivo (Fig. 2i).
Human lung organoids and bud tip progenitor organoids engraft in mice
Both organoids can engraft into immunocompromised mice. Human lung organoids are able to
engraft into ectopic vascular beds (i.e., epididymal fat pad; Fig. 2b–d), and bud tip progenitor
organoids have been shown to engraft into the injured mouse airway (Fig. 2i), suggesting potential in
regenerative medicine. However, a deeper understanding of these cells is required before they could
be used in a clinical setting.
Fig. 2 | Applications of the protocol. a–e, Potential applications for human lung organoids. a, Organoid lumens can
be microinjected, as done here with 1 µL of 4-kDa FITC–dextran suspended in PBS at a concentration of 2 mg/mL
(green)20. Images show organoids 1 h after injection. Scale bar, 200 µm (applies to both images). b, Human lung
organoids can be seeded on a bioengineered poly(lactic-co-glycolic acid) (PLG) scaffold and transplanted into the
mouse fat pad (full methods can be found in ref. 16). This structure can grow to more than 1 cm in diameter in
~8 weeks. c, Transplanted human lung organoids contain airway-like structures, as visualized here by H&E staining
after 8 weeks16. Scale bar, 200 µm. d, After 8 weeks of transplantation, human lung organoids (HLOs) contain
NKX2.1+ airway epithelial structures that stain positive for human nuclear antigen (HUNU) and exhibit multiciliated
cells that stain positive for acetylated tubulin (ACTTUB; a video showing the resulting functional beating ciliated cells
is available from ref. 16). Further, these structures contain epithelial tubes with P63+ basal-like cells lining the
basolateral surface of the tube and FOXJ1+ ciliated cells lining the interior luminal side of the pseudostratiﬁed
epithelium. Scale bars, 50 µm. e, Roughly 50 human lung organoids were seeded onto a decellularized human lung
matrix punch in a 96-well plate. Human lung organoid seeded cells gave rise to epithelial structures expressing
multiciliated-cell markers acetylated tubulin and FOXJ1 after 40 d of culture. Scale bars, 100 µm. f–i, Applications for
bud tip progenitor organoids. f, Bud tip progenitor organoids can be microinjected with ﬂuids, as done here with 1 µL
of 4-kDa FITC–dextran suspended in PBS at a concentration of 2 mg/ml (green)20. Five organoids were injected.
Images show organoids 1 h after injection. Scale bar, 500 µm. g, Bud tip progenitor cells in bud tip progenitor
organoids are capable of undergoing multilineage differentiation into airway and alveolar-like cells, and this system
can be used to interrogate mechanisms of lineage decisions in vitro. Bud tip progenitor organoids treated for 24 d
with FGF7 alone generated cells that expressed the AECI marker HOPX and AECII markers pro-surfactant protein C
(PRO-SPC) and surfactant protein B (SFTPB). Alevolar-like cells made up roughly 50% of these organoids. Airway-
like cells were also generated, including cells that stained positive for goblet cell marker MUC5AC and
neuroendocrine markers chromagranin A (CHGA) and synaptophysin (SYN). Scale bar, 50 µm. i, Bud tip progenitor
organoids can be expanded in culture and injected directly into the injured mouse airway, where they can engraft. In
this experiment, bud tip progenitor organoids were generated from the iPSC 20-1 tet-O–GFP cell line to provide
doxycycline (DOX)-inducible GFP expression. Organoids were grown, expanded and dissociated to single cells, and
roughly 500,000 bud tip progenitor organoid cells were injected into the mouse airway 24 h after airway injury with
naphthaline. Mice were allowed to recover for 6 weeks. During the ﬁfth week after cell injection, mice were given
DOX-treated water; surviving human cells with access to the host blood stream could then begin expressing GFP
upon exposure to DOX17. Engrafted cells expressed the human nuclear marker NuMA, as well as markers of
differentiation including multiciliated-cell markers (acetylated tubulin) and the goblet cell marker MUC5AC. These
cells integrated seamlessly with the host epithelium. Further, cells were able to receive signals from the host
bloodstream, as bud tip progenitor cells derived from a tet-O–GFP iPSC line were able to turn on GFP expression
when the host mouse was given DOX in drinking water. Scale bars, 50 µm. Detailed information about antibodies
used for staining can be found in Table 3. b–d, Reproduced with permission from ref. 16, eLife Sciences Publications
(licensed under CC BY-NC-ND 4.0, https://creativecommons.org/licenses/by/4.0/). e, Reproduced with
permission from ref. 15, eLife Sciences Publications (licensed under CC BY-NC-ND 4.0, https://creativecommons.
org/licenses/by/4.0/). g–i, Reproduced with permission from ref. 17, Elsevier (licensed under CC BY-NC-ND 4.0,
https://creativecommons.org/licenses/by/4.0/).
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Comparison to other methods
The protocol described here outlines methods to generate 3D foregut spheroids, which can be further
cultured in a 3D environment such as Matrigel to generate (i) human lung organoids containing lung
epithelium and mesenchyme or (ii) a highly expandable population of bud tip progenitor organoids
containing SOX9+SOX2+ bud tip progenitors that are similar to bud tip progenitors in the native
developing fetal lung. Other methods to direct the differentiation of hPSCs to endoderm25, foregut13,
and lung lineages on a monolayer11,12,14 and in 3D culture have been described15,17,26–31. Each of
the different 2D and 3D systems described has unique features, and each has strengths and
limitations that should be considered to ensure that the model system being used matches the
scientiﬁc question at hand.
The ﬁrst reported studies of directed differentiation of hPSCs into a lung lineage used monolayer
cultures11,12,32–34 in which hPSCs were directed ﬁrst to deﬁnitive endoderm25, then to anterior foregut
endoderm13, and ﬁnally to an NKX2.1+ lung lineage.
More recent reports, including our own, have focused on the generation of 3D lung tissue in
attempts to recapitulate more complex elements of a native organ15,17,26–31. The organoid models
described here and in other reports are summarized in Table 1. In a recent study, Chen et al.28
directed hPSC differentiation on a monolayer to early NKX2.1+ lung progenitors, which formed
clumps of cells that could be dissociated from the monolayer and placed in a droplet of Matrigel with
FGF7, FGF10, CHIR-99021 and ATRA, giving rise to 3D structures termed lung bud organoids
(LBOs). A subset of LBOs cultured in Matrigel quickly formed branched structures that could be
manipulated by plating density. Epithelial cells expressed markers of goblet cells and AECII cells,
although many other cell types (P63+ cells, SCGB3A2+ secretory and multiciliated cells) were not
detected. Although mesenchymal cells were present in these cultures, the proportion declined to <2%
of total cells after prolonged culture in Matrigel. Transplantation of LBOs into mouse kidney capsule
yielded NKX2.1+ epithelial tubes that formed branch-like structures surrounded by lung mesench-
yme. Tips of these branch-like structures did not express SOX2 but were positive for the AECII
markers SFTPB and SFTPC, which suggests that these structures were patterned into alveolar-like
structures. The stalks of these tubules contained cells that expressed multiciliated and mucus-
producing cell markers. Mucus was found within lumen, suggesting functionality of mucus-
producing cells. Of note, when LBOs grown in vitro in Matrigel were treated with respiratory
syncytial virus, they exhibited epithelial shedding, characteristic of the physiological lung response28.
This LBO model is thus well suited for experiments exploring the effect of infections or diseases
that affect the mucus-producing cells or AECIIs of the lung epithelium, such as inﬂuenza. Further,
LBOs could be valuable tools for further exploration of the mechanisms regulating epithelial
branching events.
Following directed differentiation to foregut endoderm/lung lineages, several reports have used
cell-sorting techniques to isolate early-lung-lineage progenitors for subsequent 3D culture26,27,29–31.
Gotoh et al.29 identiﬁed carboxypeptidase M (CPM) as a marker of ventral foregut endoderm. 3D
culture of sorted CPM+ cells in coculture with human fetal ﬁbroblasts gave rise to organoids with
cells expressing alveolar epithelial cell markers and lamellar bodies. This technique was later built
upon by Konishi et al.30, who reported that CPM+ organoids could be cultured in a commercially
available medium specialized for air–liquid interface culture and supplemented with DAPT. After
42–56 d in culture, the CPM+ cells gave rise to airway-like organoids with functional multiciliated
and mucus-producing cells. Given the presence of functional multiciliated and mucus-producing
cells, this model is ideal for interrogating diseases affecting the airway, such as ciliopathies, cystic
ﬁbrosis or the process of goblet cell hyperplasia after infection. More recently, Yamamoto et al.35
demonstrated that CPM+ cells can be differentiated into AECII-like organoids via coculture with fetal
ﬁbroblasts, or in deﬁned medium.
Hawkins et al.31 described the generation of an NKX2.1-reporter hPSC line (RUES2), which
allowed isolation of NKX2.1+ cells. NKX2.1+ cells plated in 3D formed epithelial-only organoid
structures. Transcriptomic proﬁling of these cells identiﬁed cell-surface markers (CD47hiCD26lo) that
could allow for the prospective isolation of NKX2.1+ cells without the use of reporter cell lines. This
method was built upon by Jacob et al.26 and McCauley et al.27, who showed that modulation of
growth factor signaling in these cultures leads to the generation of distal (alveolar-like) or proximal
(airway-like) organoids that are epithelial only, respectively. Proximal airway organoids have func-
tional multiciliated and mucus-producing cells and have been shown to be able to model some
hallmarks of cystic ﬁbrosis when CF-iPSC cell lines are used. These systems are ideal for studying
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airway diseases that affect functional epithelial cells, such as cystic ﬁbrosis and ciliopathies, and
are also highly expandable, which makes them potential candidates for large drug-screening
platforms.
In addition to hPSC-derived lung organoid models, it should be noted that many more in vitro
human lung models have been generated from primary human adult or fetal lung tissue. These
systems have been thoroughly reviewed elsewhere36–38 and are ideal for interrogating lung diseases, as
samples can be patient speciﬁc; they also may be critical for personalized medicine and screening for
therapeutic responsiveness.
Several of the models described above have excelled at generating functional and differentiated
epithelial cell types that may be uniquely suited to the interrogation of disease phenotypes. In
contrast, the protocols described here generate fetal-like lung tissue that is ideal for studies of human
lung development. One additional difference between other methods and those described here is that
self-aggregating 3D foregut spheroids form spontaneously and do not require cell dissociation, cell
sorting or other specialized techniques. Foregut spheroids can be cultured in a Matrigel droplet and
further differentiated into two distinct 3D lung organoid models (Fig. 1).
Limitations of the protocol
The HLO model (Fig. 1a) generates fetal-like airway epithelium and surrounding mesenchyme, as
well as a population of cells that express alveolar cell markers. However, as with all other 3D organoid
models described here, transplantation into a mouse is required for the generation of fully mature
structures and cell types. The largest limitation to using this model to study disease and development
is that HLOs take ~60 d to form and are not highly expandable, which limits the amount of material
available for study. For both protocols, the use of Matrigel or other animal-derived products such as
serum (used during endoderm differentiation) remains a barrier to translation. However, serum-free
alternatives have been developed for other organoid models28,39, and therefore the protocol should be
adaptable to the use of deﬁned serum (dFBS), serum-free protocols, or fully synthetic hydrogels,
which will aid in progress toward translation18,40. For example, human intestinal organoid protocols5
initially developed for use with serum now have commercially available serum-free alternatives (e.g.,
STEMdiff intestinal organoid kit, Stemcell Technologies), which suggests that these systems are fairly
ﬂexible and can be modiﬁed depending on the speciﬁc needs of the end user. In some cases, such as
those where maintenance of a mesenchymal population is desirable (e.g., human lung organoids15),
serum may be required, as the growth of lung organoids plus mesenchyme in serum-free medium was
shown to lead to mesenchymal loss over time28.
The bud tip progenitor organoid model (Fig. 1b) generates a highly enriched population of lung
bud tip progenitors from hPSCs in 22 d in a serum-free environment, but this population is com-
posed largely of undifferentiated progenitor cells. Thus, this system is not ideal for studying differ-
entiated cell function (e.g., airway function or alveolar function). Understanding the mechanisms by
which bud tip progenitor cells differentiate into a speciﬁc functional epithelial cell type remains a
large gap in knowledge in the ﬁeld, which the bud tip progenitor organoid model will help to close.
Moreover, our initial attempts to differentiate bud tip progenitors used a stochastic differentiation
strategy in which cells were provided with a supportive growth environment containing only FGF7
and were allowed to spontaneously differentiate. In this context, bud tip progenitors gave rise to
immature alveolar and airway cell types. However, we noted that these cells exhibited a bias toward
mucus-producing cells in vitro; this result is not well understood. Much further progress will be
required before truly controlled directed differentiation is achieved and becomes a viable option for
regenerative medicine.
Expertise needed to implement the protocol
Any student or postdoctoral fellow with hPSC culture experience can use this protocol. No core
facilities are required. All equipment is standard to most cell culture facilities, and reagents can be
purchased from standard scientiﬁc vendors.
Materials
Biological materials
hESCs or hiPSCs. This protocol can be performed with any hESC or human iPSC line. We have
successfully used hESC lines H1, H9, UM63-1 and UM77-1 (NIH registry nos. 0277, 0062, 0043 and
0278, respectively). H9 and H1 cell lines were obtained from the WiCell Research Institute, and UM
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63-1 and 77-2 lines were obtained from the University of Michigan. We have also successfully
used iPSC line 20-1 (ref. 5). In our experience, genetically modiﬁed reporter lines derived from
parental cell lines perform as well as their unmodiﬁed counterparts (e.g., H9 mCherry and iPSC 20-1
TetO-GFP). ! CAUTION Research using hPSCs must be conducted in accordance with federal, state,
local and institutional ethical guidelines and regulations. ! CAUTION Cell lines should be regularly
checked for mycoplasma contamination and tested via cell line authentication methods (e.g., short
tandem repeat proﬁling) to ensure proper cell line identity.
Reagents
Cell growth media and supplements
● 1-thioglycerol (Sigma-Aldrich, cat. no. M6145)
● Activin A (R&D Systems, cat. no. 338-AC)
● Advanced DMEM (Thermo Fisher Scientiﬁc, cat. no. 12491015)
● ATRA (Stemgent, cat. no. 04-0021, CAS number 302-79-4)
● B27 supplement (Thermo Fisher Scientiﬁc, cat. no. 17504044)
● BSA (Sigma-Aldrich, cat. no. A9647)
● CHIR-99021 (Stemcell Technologies, cat. no. 72054)
● DMEM/F12 (no glutamine (DMEM/F12); Thermo Fisher Scientiﬁc, cat. no. 21331020 or 21331-020)
● FBS (Thermo Fisher Scientiﬁc, cat. no. 16000044)
● FGF10 (recombinant human ﬁbroblast growth factor 10; R&D Systems, cat. no. 345-FG, or made
in-house as previously described17)
● FGF4 (recombinant human ﬁbroblast growth factor 4; R&D Systems, cat. no. 7460-F4, or made
in-house as previously described17)
● FGF7 (recombinant human ﬁbroblast growth factor 7; R&D Systems, cat. no. 251-KG/CF)
● GlutaMAX (100×; Thermo Fisher Scientiﬁc, cat. no. 35050061)
● HEPES buffer (1 M; Thermo Fisher Scientiﬁc, cat. no. 15630080)
● HyClone-deﬁned FBS (dFBS; Thermo Fisher Scientiﬁc, cat. no. 10437010)
● L-ascorbic acid (Sigma-Aldrich, cat. no. A4544, CAS number 50-81-7)
● mTeSRTM1 (Stemcell Technologies, cat. no. 85850)
● N-2 supplement (Thermo Fisher Scientiﬁc, cat. no. 17502048)
● NOGGIN (R&D Systems, cat. no. 6057)
● Penicillin–streptomycin (100×; Thermo Fisher Scientiﬁc, cat. no. 15140122)
● RPMI 1640 medium (Thermo Fisher Scientiﬁc, cat. no. 11875119)
● SB431542 (Stemgent, cat. no. 04-0010)
● Smoothened agonist (SAG; Enzo Life Sciences, cat. no. ALX-270-426-M001)
Matrices, enzymes and other reagents
● Dispase (Thermo Fisher Scientiﬁc, cat. no. 17105041)
● Dimethyl sulfoxide (DMSO; sterile-ﬁltered; Sigma-Aldrich, cat. no. D2650, CAS number 67-68-5)
● Matrigel basement membrane matrix growth factor reduced (Corning, cat. no. 354230). Separate the
volume of Matrigel into aliquots that will yield 100 µg/mL when diluted in 12 mL of liquid. A protein
concentration is provided with the product speciﬁcation sheet. c CRITICAL Matrigel is used for
coating plates to maintain hPSCs.
● Matrigel basement membrane matrix (Corning, cat. no. 354234) c CRITICAL This reagent is used for
culturing organoids in droplets. c CRITICAL Lot-to-lot variation occurs. Ensure that the Matrigel has
a protein concentration greater than 8.0 mg/mL. If the protein concentration is higher, dilute to 8.0
mg/mL with DMEM/F12. If the protein concentration is too low, organoids will sink to the bottom of
the droplet and adhere to the plastic culture dish, which will cause them to lose their 3D structure and
is likely to change the fate of the cells.
● Paraﬁlm M wrapping ﬁlm (Thermo Fisher Scientiﬁc, cat. no. S37440)
● Sterile phosphate-buffered saline (PBS; pH 7.4; Thermo Fisher Scientiﬁc, cat. no. 10010049)
● Sterile dH2O (Thermo Fisher Scientiﬁc, cat. no. 15230170)
Equipment
● Tissue culture hood
● Cell culture incubator
● Dissecting microscope
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● Centrifuge
● Pipet-Aid (or similar; e.g., Fisher Scientiﬁc, cat. no. 1368106)
● Cell scraper (VWR, cat. no. 76036-004)
● Steriﬂip (Millipore, cat. no. EW-29969-24)
● Six-well plates (tissue-culture treated; Thermo Fisher Scientiﬁc, cat. no. 140675)
● 24-well plates (tissue-culture treated; Thermo Fisher Scientiﬁc, cat. no. 142475)
● 10-mL serological pipettes (Thermo Fisher Scientiﬁc, cat. no. 07200574)
● 1.5-mL tubes (Thermo Fisher Scientiﬁc, cat. no. 02682000)
● 15-mL conical centrifuge tubes (Falcon; Thermo Fisher Scientiﬁc, cat. no. 1495953A)
● 50-mL conical centrifuge tubes (Falcon; Thermo Fisher Scientiﬁc, cat. no. 1443222)
● 27-gauge needles (BD PrecisionGlide, single-use needles; Thermo Fisher Scientiﬁc, cat. no. 1482113B)
● 1-mL syringes (BD disposable syringes with Luer-Lok Tips; Thermo Fisher Scientiﬁc, cat. no. 1482330)
Reagent setup
Human pluripotent stem cell culture
Culture of hPSCs has been described elsewhere, such as in the Harvard Stem Cell Institute StemBook
Protocols (http://www.stembook.org/protocols/pluripotent-cells). Detailed instructions are provided
here to ensure the successful completion of this protocol. More technical information regarding
the maintenance of hPSCs with mTeSRTM1 can be found at the Stemcell Technologies website
(https://www.stemcell.com/guide-to-passaging-human-pluripotent-stem-cells-using-mtesr1.html).
Aliquoting Matrigel for plate coating to maintain hPSCs
Thaw matrix growth-factor-reduced (BM GF-reduced Matrigel) Matrigel at 4 °C overnight. Separate
BM GF-reduced Matrigel into aliquots as indicated on the manufacturer product sheet (lot depen-
dent). The product speciﬁcation sheet will provide a protein concentration for each lot of Matrigel.
Separate the volume of Matrigel into aliquots that will lead to a 100 µg/mL hESC-qualiﬁed
GF-reduced Matrigel when diluted into 12 mL of cold DMEM F/12. 12 mL of 100 µg/mL Matrigel is
enough to coat one 24-well plate or two 6-well plates. Aliquots can be stored at −80 for up to
6 months.
Coating plates with basement membrane growth-factor-reduced Matrigel ● Timing 15–30 min to
set up; 1 h to overnight incubation
Six-well tissue culture plates are coated with a thin layer of Matrigel to improve adhesion of
stem cells. For routine maintenance of hPSCs, six-well plates are used. For differentiation, 24-well
plates are used, and the number of wells can be scaled according to the needs of an individual
experiment. The following procedure provides instructions for the preparation of two 6-well
plates or one 24-well plate. Plates can be prepared 1 h before passaging of cells and left to
coat at room temperature (20–25 °C) in a sterile hood, or plates can be coated up to 1 week
before cells are split and stored at 4 °C with the plate wrapped in Paraﬁlm to prevent evaporation.
When you are ready to coat plates, remove one aliquot of basement membrane growth-factor-
reduced Matrigel from −80 °C and leave it on ice until completely thawed. This aliquot corresponds
to a volume of Matrigel that will yield a concentration of 100 µg/mL of protein when diluted into
12 mL of liquid. Each lot of hESC-qualiﬁed Matrigel comes with a protein concentration supplied by
the manufacturer. Gently pipette the thawed basement membrane growth-factor-reduced Matrigel
into 12 mL of cold DMEM/F12. Use immediately or store at 4 °C for up to 1 week. Do not agitate
Matrigel while it is thawing, to avoid premature polymerization. Add 1 mL of diluted Matrigel to each
well of a 6-well plate or 0.5 mL of thawed Matrigel to each well of a 24-well plate. Gently swirl or tap
the plate to ensure that the entire bottom of each well is covered. Let plates sit for 1 h at room
temperature (20–25 °C) before use, or wrap the edges of the plate with Paraﬁlm and store at 4 °C for
up to 1 week.
Preparing Matrigel before making Matrigel droplets to culture organoids
Basement membrane Matrigel should be stored at −80 °C and thawed overnight at 4 °C before use.
Dilute basement membrane Matrigel with DMEM/F12 to a concentration of 8.2 mg/mL of protein.
c CRITICAL When working with Matrigel, keep it on ice at all times and work quickly. Matrix will
begin to solidify as it warms up.
NATURE PROTOCOLS PROTOCOL
NATURE PROTOCOLS | VOL 14 | FEBRUARY 2019 | 518–540 |www.nature.com/nprot 527
Dispase
Prepare a 5 mg/mL solution of dispase powder with DMEM/F12. Make 2-mL aliquots in 15-mL
conical tubes and store at −20 °C for up to 1 year. When it is time to use the solution, add 8 mL of
DMEM/F12 to a 2-mL aliquot of dispase for a working concentration of 1 mg/mL. Store at 4° for up
to 1 month.
Growth factors and small molecules
Dilute, separate into aliquots, and store according to the manufacturer’s instructions. Once thawed,
growth factors and small molecules can be kept at 4 °C for up to 2 weeks.
Ascorbic acid
To make a 50 mg/mL solution, dissolve 500 mg of L-ascorbic acid into 10 mL of tissue-culture-grade
sterile water in a 50-mL conical tube. In a tissue culture hood, ﬁlter this solution using a 0.22-µm
Steriﬂip ﬁlter. Make aliquots of 50 µL and store at −20 °C for up to 1 year. Use a fresh aliquot each
time; do not store a thawed aliquot for reuse.
Deﬁnitive endoderm differentiation medium for use on day 2
Dilute HyClone FBS in RPMI basal medium to 0.2% (vol/vol) concentration for day-2 endoderm
differentiation. To make day-2 endoderm medium for all wells of a single 24-well plate, add 24 µL of
HyClone FBS to 12 mL of RPMI medium. Details are also included in Table 2.
Deﬁnitive endoderm differentiation medium for use on days 3 and 4
Dilute HyClone FBS in RPMI basal medium to a 2% concentration for days 3 and 4 of
endoderm differentiation. To make basal medium for 2 d for a single 24-well plate, add 480 µL of
HyClone FBS to 24 mL of RPMI medium. Store at 4 °C overnight between uses. Details are also
included in Table 2 .
Foregut differentiation medium
Make foregut basal medium by adding 1× N-2, 1× B27, 10 mM HEPES, 1× GlutaMAX and 1×
pen–strep to advanced DMEM/F12 in a sterile hood. Store at 4 °C for up to 2 months. On the day of
use, add 10 µM SB431542, 200 ng/mL Noggin, 1 µM SAG, 500 ng/mL FGF4 and 2 µM CHIR99021.
Once growth factors and small molecules have been added, use on the same day; do not store. Details
are also included in Table 2.
Human lung organoid medium
On the day of use, add 1% (vol/vol) FBS and 500 ng/mL FGF10 to foregut differentiation medium.
50 mL is enough to feed a 24-well plate for roughly 2 weeks. Store at 4 °C for up to 2 weeks. Details
are also included in Table 2.
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Bud tip progenitor organoid basal medium
First, prepare BSA by taking a 500-mL bottle of DMEM/F12 and transferring 10 mL of DMEM/F12
from the 500-mL bottle into a 50-mL conical tube. Weigh out 0.25 g of BSA and add to the DMEM/
F12 aliquot. Warm the aliquot in a water bath for 15 min with occasional gentle agitation to dissolve
the BSA. In a tissue culture hood, ﬁlter the dissolved solution through a Steriﬂip ﬁlter. Add the BSA
solution back to the DMEM/F12 bottle in a sterile hood.
Table 3 | Antibody information
Primary antibody Source Cat. no. Dilution (sections) Clone
Chicken anti-GFP Abcam Ab13970 1:500 Polyclonal
*Biotin–goat anti-TP63 R&D systems BAF1916 1:500
*Biotin–mouse anti-MUC5AC Abcam ab79082 1:500 Monoclonal
Goat anti-CC10 (SCGB1A1) Santa Cruz Biotechnology sc-9770 1:200 C-20
Goat anti-chromogranin A (CHGA) Santa Cruz Biotechnology sc-1488 1:100 C-20
Goat anti-SOX2 Santa Cruz Biotechnology Sc-17320 1:200 Polyclonal
Goat anti-vimentin (VIM) Santa Cruz Biotechnology sc-7558 1:100 S-20
Mouse anti-acetylated tubulin (ACTUB) Sigma-Aldrich T7451 1:1,000 6-11B-1
Mouse anti-α-smooth muscle actin (SMA)*Cy3-conjugated Sigma C6198 1:400 Monoclonal
Mouse anti-E-cadherin (ECAD) BD Transduction Laboratories 610181 1:500 36/E-cadherin
Mouse anti-FOXJ1 eBioscience 14-9965-82 1:500 2A5
Mouse anti-human nuclear antigen (HuNu) Abcam ab191181 1:250 Monoclonal
Mouse anti-surfactant protein B (SFTPB) Seven Hills Bioreagents Wmab-1B9 1:250 Monoclonal
Rabbit anti-HOPX Santa Cruz Biotechnology Sc-30216 1:250 Polyclonal
Rabbit anti-NKX2.1 Abcam ab76013 1:200 EP1584Y
Rabbit anti-nuclear mitotic aparatus—human (NuMa) Thermo Scientiﬁc PA5-22285 1:500 Polyclonal
Rabbit anti-PDGFRα Santa Cruz Biotechnology sc-338 1:100 C-20
Rabbit anti-pro-surfactant protein C (pro-SFTPC) Seven Hills Bioreagents Wrab-9337 1:500 Polyclonal
Rabbit anti-SOX9 Millipore AB5535 1:500 Polyclonal
Rabbit anti-synaptophysin Abcam AB32127 1:500 Monoclonal
Secondary antibody Source Cat. no. Dilution
Donkey anti-goat 488 Jackson ImmunoResearch 705-545-147 1:500
Donkey anti-goat 647 Jackson ImmunoResearch 705-605-147 1:500
Donkey anti-goat Cy3 Jackson ImmunoResearch 705-165-147 1:500
Donkey anti-mouse 488 Jackson ImmunoResearch 715-545-150 1:500
Donkey anti-mouse 647 Jackson ImmunoResearch 415-605-350 1:500
Donkey anti-mouse Cy3 Jackson ImmunoResearch 715-165-150 1:500
Donkey anti-rabbit 488 Jackson ImmunoResearch 711-545-152 1:500
Donkey anti-rabbit 647 Jackson ImmunoResearch 711-605-152 1:500
Donkey anti-rabbit Cy3 Jackson ImmunoResearch 711-165-102 1:500
Donkey anti-goat 488 Jackson ImmunoResearch 705-545-147 1:500
Donkey anti-goat 647 Jackson ImmunoResearch 705-605-147 1:500
Donkey anti-goat Cy3 Jackson ImmunoResearch 705-165-147 1:500
Donkey anti-mouse 488 Jackson ImmunoResearch 715-545-150 1:500
Donkey anti-mouse 647 Jackson ImmunoResearch 415-605-350 1:500
Donkey anti-mouse Cy3 Jackson ImmunoResearch 715-165-150 1:500
Donkey anti-rabbit 488 Jackson ImmunoResearch 711-545-152 1:500
Donkey anti-rabbit 647 Jackson ImmunoResearch 711-605-152 1:500
Donkey anti-rabbit Cy3 Jackson ImmunoResearch 711-165-102 1:500
Streptavidin 488 Jackson ImmunoResearch 016-540-084 1:500
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Add 1× N-2, 1× B27, 1× glutamine and 1× pen–strep to the DMEM/F12 + BSA in a sterile hood
to complete the bud tip progenitor organoid basal medium. Store at 4 °C for up to 2 months. Details
are also included in Table 2.
Bud tip progenitor organoid complete medium for the generation and maintenance of bud tip
progenitor organoids
When ready to generate or maintain bud tip progenitor organoids, add the appropriate supplements
to the bud tip progenitor organoid basal medium. To make a 50-mL volume of bud tip progenitor
organoid complete medium, place 50 mL of bud tip progenitor organoid basal medium in a 50-mL
conical tube and add 50 µg/mL ascorbic acid and 0.4 µM monothioglycerol. This is the
complete medium.
Then add 3 µM CHIR99021, 10 ng/mL FGF7 and 50 nM ATRA. 50 mL of medium is enough to
feed a single 24-well plate for ~2 weeks. Store at 4 °C for up to 2 weeks.
Procedure
Splitting of human pluripotent stem cell culture ● Timing 30–60 min
c CRITICAL Proper maintenance of hPSCs is essential for successful completion of this protocol.
Seeding density and colony size must be closely monitored to ensure that no premature differentiation
occurs. See Figs. 3 and 4 for visual guides. Note that we do not use feeder layers to maintain hPSCs.
c CRITICAL This procedure was developed and optimized for hPSCs maintained in six-well tissue
culture dishes coated with 100 µg/mL basement membrane growth-factor-reduced Matrigel and fed
daily with mTeSRTM1. For routine maintenance, cells are kept in a tissue-culture-grade incubator with
95% air and 5% CO2 and are maintained in a sterile environment.
c CRITICAL This section describes how to establish cell cultures before beginning the differentiation
protocol. It describes splitting 4 wells of a 6-well plate into all the wells of one 24-well plate.
Alternatively, one well of a six-well plate can be split into six wells of a six-well plate to maintain hPSCs.
1 Undifferentiated hPSC colonies that are ~75–85% conﬂuent will appear rounded with well-deﬁned
smooth edges (Fig. 3a,g). Colonies with jagged edges, many bright white raised spots or ‘donut
holes’ have probably begun to differentiate, and should not be used for this protocol (Fig. 4a).
If there are only a few differentiated areas, scrape differentiated colonies off with a pipette tip under
a dissecting microscope before splitting (Fig. 4a, arrow).
2 Warm dispase, mTeSRTM1 and DMEM/F12 in a 37 °C water bath for ~10 min.
3 Add 1 mL of 1 mg/mL dispase solution to each well that will be split. Return to incubator for
5–10 min. Observe colonies under a microscope, and proceed when the edges of the colonies begin
to lift off the tissue culture dish.
4 Carefully aspirate dispase. Colonies will still be attached to the dish.
5 Gently wash cells three times with prewarmed DMEM/F12.
6 Add 3.5 mL of mTeSRTM1 medium to each well that will be split. This includes an extra 0.5 mL of
medium per well to accommodate for the volume that may be lost during trituration and transfer to
new plates.
7 Use a cell scraper to gently scrape all cells off the bottom of the dish.
8 Using a 10-mL serological pipette and automatic dispenser, triturate colonies into small clumps by
doing the following: pull all cells up into the pipette, place the pipette ﬁrmly on the bottom of the
dish and pipette down to shear the cell colonies apart. Check under a dissecting scope under low
magniﬁcation (images in Fig. 2b shown at 0.7× magniﬁcation) to assess the size of the sheared
colonies. Repeat this process until colonies are small enough that they do not immediately sink to
the bottom of the dish. Figure 4b shows sheared colonies in suspension under a dissecting
microscope that are too large. Aim to shear colonies until their size is similar to what is shown in
Fig. 3h. Cell clumps should be small enough to remain ﬂoating in suspension, but should not be
triturated all the way to single cells.
c CRITICAL STEP If sheared cell colonies are too large during splitting, proper differentiation will
be difﬁcult to achieve during this protocol (Fig. 4d).
9 Aspirate the diluted Matrigel media that was used to coat each well of the 24-well dish. If splitting
into a six-well dish, add 1 mL of fresh, prewarmed mTeSRTM1 plus 0.5 mL of triturated hPSC
clumps. If splitting into a 24-well dish for differentiation, add 0.5 mL of triturated hPSCs to
each well.
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Fig. 3 | Human pluripotent stem cell splitting and directed differentiation. a–f, Schematic of the timeline and experimental procedures. g–i, Bright-
ﬁeld images of hPSCs during growth and splitting procedures. Insets are inverted images taken at the same magniﬁcation to help visualize cell density
and colony shape. Scale bars, 1 mm or 100 µm as noted. a, First, treat hPSCs with dispase. g, Bright-ﬁeld image indicates proper conﬂuency and healthy
colony shape. These cells are ready to split. b, Wash cells, scrape them up with a cell scraper, and use a serological pipette to mechanically break apart
colonies. h, Bright-ﬁeld image shows the proper size of broken-up colonies in suspension. These cells are ready to be seeded into a 24-well plate.
c, Seed cells into a 24-well plate. i, Bright-ﬁeld image showing ﬂoating colonies. These colonies are evenly dispersed throughout the well and can be
placed in the incubator overnight. 24 h after seeding, colonies should cover roughly 50% of the bottom of the well and should be evenly dispersed.
d, Begin endoderm differentiation protocol. j–l, Bright-ﬁeld images showing typical morphology in the cell monolayer throughout endoderm
differentiation at low magniﬁcation through a dissecting scope (j, top row; scale bar, 1 mm) or at higher magniﬁcation under an inverted microscope (j,
bottom row; scale bar, 100 µm). e, Begin anterior foregut differentiation protocol. k, Bright-ﬁeld images showing typical morphology in the cell
monolayer throughout anterior foregut differentiation. Foregut spheroids begin to form around day 3–4 of anterior foregut differentiation (k, top row,
white arrows). Shown at low magniﬁcation through a dissecting scope (k, top row; scale bar, 1 mm) and at higher magniﬁcation under an inverted
microscope (k, bottom row; scale bar, 100 µm). l, A digitally zoomed image shows what foregut spheroids look like on the culture plate on day 8 of the
differentiation protocol. f, Collect ﬂoating spheroids, mix them with Matrigel, and put them into droplets on a fresh 24-well plate.
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10 Under the dissecting microscope, aggressively shake the plate in a side-to-side motion to ensure
that hPSCs are evenly distributed throughout the entire well, as seen in Fig. 2c. One can also achieve
this by tapping the side of the 24-well plate several times.
c CRITICAL STEP If all of the hPSCs congregate to the center of the well (as shown in Fig. 4c),
spheroids will not form.
Directed differentiation into endoderm and anterior foregut spheroids ● Timing 9–12 d:
4 d deﬁnitive endoderm differentiation, 4–5 d anterior foregut endoderm differentiation
11 Allow passaged cells to become 45–75% conﬂuent before starting the protocol. This may take 1–2 d
after passaging.
c CRITICAL STEP If conﬂuency is too low, insufﬁcient cells will remain after endoderm
differentiation. If conﬂuency is too high, differentiation in the center of the colonies may be
incomplete and result in reduced spheroid formation. Figure 4d shows images of improper seeding
density and of colonies that are too large. Proper conﬂuency of cells in a 24-well plate ready to
proceed to endoderm differentiation is shown in Fig. 3i.
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Fig. 4 | Common errors and troubleshooting. a, Before splitting hPSCs, check that there are no obvious
differentiated colonies on the plate. Scrape away any abnormal colonies using a sterile pipette tip before splitting
hPSCs into 24-well plates. The arrow indicates an area of hPSC differentiation visible as a raised white structure that
should be scraped away before splitting. Scale bar, 1 mm. b, When breaking up hPSC colonies for splitting, ensure
that the colonies are broken up to a small enough size. These images show colonies that are still too large. Continue
breaking up colonies before proceeding with splitting cells. Scale bar, 1 mm. c, After hPSC colonies have been placed
in a 24-well dish, shake the plate vigorously under a dissecting microscope to ensure that the cells are evenly
dispersed. In this image the majority of cells are still clustered in the center of the well. This will cause an uneven
growth pattern, and the differentiation will not yield spheroids. Shake cells before proceeding with differentiation.
Scale bar, 1 mm. d, Bright-ﬁeld images at low (top row; scale bar, 1 mm) and high (bottom row; scale bar, 100 µm)
magniﬁcation showing culture conditions on day 0 of differentiation that are likely to fail to form spheroids. If the
seeding density is too low or too high or if colony sizes are too big because the hPSC colonies were not sufﬁciently
sheared after splitting, the differentiation protocol will not be successful. The arrow in the high-density seeding
column indicates cells that have become conﬂuent in the center of the well, which will lead to uneven differentiation
and likely failure of the protocol to yield foregut spheroids.
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12 Feed cells for 4 d with deﬁnitive endoderm differentiation medium (each day, change the medium
by removing the existing medium and replacing it with 0.5 mL of medium per well of the 24-well
plate). The appropriate media to use each day are listed below and in Table 2. Also check that cell
morphology is as expected by comparing with the representative images shown in Fig. 3j.
Day Medium
1 RPMI + 0% (vol/vol) FBS + 100 ng/mL activin A
2 RPMI + 0.2% (vol/vol) FBS + 100 ng/mL activin A
3 RPMI + 2% (vol/vol) FBS + 100 ng/mL activin A
4 RPMI + 2% (vol/vol) FBS + 100 ng/mL activin A
13 On day 5, replace medium with anterior foregut endoderm differentiation medium (0.5 mL of
foregut basal media + 10 µM SB431542 + 200 ng/mL Noggin + 1 µM SAG + 500 ng/mL FGF4 +
2 µM CHIR99021, as listed in Table 2). Replace medium on days 6, 7, 8 and 9. On days 5–9, change
media daily. Also check that cell morphology is as expected by comparing it with the representative
images shown in Fig. 3k.
14 Observe that detached, ﬂoating spheroids begin to form around days 8 and 9 of culture
(representative images are shown in Fig. 3k,l).
Collection of ﬂoating anterior foregut spheroids ● Timing 15–60 min
c CRITICAL Ensure sterile technique and a sterile environment throughout the process. This procedure
is routinely performed in a laminar ﬂow hood equipped with a stereomicroscope, or in a semi-sterile
hood (e.g., Labconco 3970321) equipped with a stereomicroscope.
c CRITICAL A video presentation of the generation of Matrigel droplets for intestinal organoid culture
has been published and can be used as a helpful reference for setting up lung organoid cultures41 (found
at the 4:15 mark of the video https://www.jove.com/video/53359/organoids-as-model-for-infectious-
diseases-culture-human-murine).
15 On day 8 or 9, place Matrigel on ice in the sterile hood.
16 Cut the tip off of a sterile p200 pipette ﬁlter tip (~5 mm) using sterile scissors or a scalpel and place
an empty 1.5-mL snap-cap tube and a new (uncoated) 24-well plate in a hood with a dissecting
microscope.
c CRITICAL STEP Some 24-well tissue culture dishes will allow Matrigel to form 3D droplets,
whereas Matrigel disperses across the surface of other dishes. Nunc cell-culture treated multidishes
allow droplets to form; other brands should be tested before transfer of Matrigel plus spheroids.
17 Place the 24-well culture plate that contains the foregut spheroids under a dissecting microscope.
Observe one well under the stereomicroscope to identify free-ﬂoating spheroids. Without
disturbing the monolayer, gently remove the free-ﬂoating spheroids by pipetting with a cut p200
pipette tip and transfer them into an empty 1.5-mL snap-cap tube. Spheroids from multiple wells
can be pooled together in a single tube. We typically pool one entire 24-well plate into one 1.5-mL
tube. Allow 5–10 min for the spheroids to settle to the bottom of the tube. Although spheroids
should settle by gravity, they can be gently spun down with a microcentrifuge on the lowest setting
for ~10 s if necessary.
18 Plate spheroids in basement membrane Matrigel (8.0 mg/mL protein concentration). To do this,
gently remove as much media as possible from the tube under the dissecting microscope using a
fresh p200 pipette. Once media has been removed, cut the tip off a fresh p200 tip. Draw up ~200 µL
of Matrigel. Place Matrigel in the tube with the spheroids and gently pipette up and down several
times to mix the spheroids in the Matrigel. Work quickly so the Matrigel does not congeal. Pipette
with care to avoid making bubbles. Draw up all the Matrigel and spheroids, and pipette ~25 µL of
the Matrigel–spheroid mixture into the center of a single well of the 24-well plate. 200 µL of starting
mixture will be sufﬁcient to make eight individual wells with a Matrigel droplet containing
spheroids.
c CRITICAL STEP We routinely draw up the entire contents of wells containing Matrigel and
spheroids into a single cut p200 tip and estimate 25 µL of droplets, but it is also acceptable to
pipette individual 25-µL droplets if greater accuracy is desired.
c CRITICAL STEP Keep the Matrigel on ice throughout the protocol to ensure that it does not
polymerize inside the bottle.
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19 Place the plate in the incubator for ~10 min until Matrigel droplets have solidiﬁed. Once droplets
have solidiﬁed, add 0.5 mL of desired media to generate either human lung organoids or epithelial
bud tip progenitor organoids (see the next step for details).
Generation of human lung organoids or bud tip progenitor organoids
20 Generate either human lung organoids (option A), which contain airway-like structures surrounded
by lung mesenchyme and a population of cells with alveolar markers, or bud tip progenitor
organoids (options B and C). Use option B if doing needle passaging. Use option C if using
bulk passaging.
(A) Generation and maintenance of human lung organoids ● Timing Organoids with airway-
like structures and surrounding mesenchyme will take ~50 d to grow and are optimal for
use on days 50–85, as this is when the organoids have the maximum amount of airway-like
structures. They need to be re-embedded in fresh Matrigel every 2–3 weeks.
(i) Add 1% (vol/vol) FBS and 500 ng/mL of FGF10 to foregut basal medium. Add 500 µL of
media to each well of spheroids, ensuring that the media completely covers the Matrigel
droplets. Change media every 3–5 d. See Table 2 for a summary of the media components.
(ii) Re-embedding of organoids. Every 2–3 weeks, or sooner if organoids appear to be
accumulating cellular debris within lumens or sinking to the bottom of the Matrigel
droplet, cut the tip off a P1000 pipette tip and gently scrape the bottom of the well to
dislodge the Matrigel droplet(s) containing organoids.
(iii) Pick up the entire droplet and surrounding media with the pipette tip and move to a Petri
dish. Under a dissecting scope in a sterile environment, use a scalpel and 27-gauge needle
to gently cut and remove the old Matrigel away from the organoids. Be cautious not to cut
the tissue. Once ﬁnished, move the now-cleaned organoids to a 1.5-mL snap-cap tube and
remove any media.
(iv) Cut the tip off a p200 pipette tip and transfer 200 µL of fresh Matrigel (kept on ice) to the
tube with the organoids; mix and draw up all Matrigel into the p200 tip. Serially pipette
~50 µL of the Matrigel–organoid mixture into single wells in a fresh 24-well plate. Aim to
put one to three organoids in each droplet.
(v) Place plate in the incubator for ~10 min, or until Matrigel droplets have solidiﬁed. Once
droplets have solidiﬁed, add 500 µL of media.
(vi) Maintain organoids for the desired time period, repeating Step 20A(ii–v) to re-embed
organoids every 2–3 weeks. Once foregut spheroids are placed in Matrigel, it takes roughly
50 d to obtain pseudostratiﬁed epithelial structures that contain basal cells, mucus-
producing cells and ciliated cells, as well as surrounding lung mesenchymal cell types and
primitive alveolar cell types. The organoids can be maintained for more than 100 d;
however, we ﬁnd that the epithelium is gradually lost over time, and utilization between 60
and 85 d is optimal.
(B) Generation and maintenance of bud tip progenitor organoids using serial needle passaging
● Timing Epithelium-only cysts will form after ~2 weeks and will contain a nearly
homogeneous population of bud tip progenitor cells. If culture is not homogeneous,
organoids with clear epithelial cystic structures can be isolated by hand at this time point
(2 weeks). This population of epithelial organoids can be maintained and expanded by
serial needle passaging for over 120 d in culture.
(i) On the day of use, add 50 µg/mL L-ascorbic acid, 0.04 µL/mL monothioglycerol, 10 ng/mL
FGF7, 50 nM ATRA and 3 µM CHIR-99021 to basal medium composed of DMEM/F12 +
N-2 supplement + B27 supplement + 1× L-glutamine + 1× pen–strep to make bud tip
progenitor organoid complete medium (as also detailed in Table 2). Feed foregut spheroids
with 500 µL of bud tip progenitor organoid complete medium.
(ii) Replace media every 3–5 d.
(iii) Needle passage. After 2–3 weeks, or sooner if organoids appear to be accumulating cellular
debris within lumens or sinking to the bottom of the Matrigel droplet, use a P1000 pipette
tip to dislodge Matrigel droplets containing organoids. Place the dislodged droplets
together into a 1.5-mL snap-cap tube.
(iv) Using a 1-mL syringe and a 27-gauge needle, draw the Matrigel and cells into the syringe
and forcefully expel the contents back into the tube. Repeat two to three times.
(v) Spin down the contents of the tube in a benchtop minicentrifuge (e.g., Thermo Fisher
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Scientiﬁc mySPIN 6 Mini Centrifuge, cat. no. 75004061) at full speed (6,300g) for ~3–5 s. It
is also acceptable to spin cells down at 300g for 3 min at 4 °C. Epithelial fragments will
settle to the bottom, and Matrigel will remain suspended in the media.
(vi) Under a dissecting scope in a sterile hood, use the needle and syringe to remove the media
and Matrigel from the tube, leaving behind the cell pellet.
(vii) Add ~200 µL of fresh ice-cold Matrigel to the tube using a p200 pipette with the tip cut off.
Mix the cells and Matrigel, avoiding bubbles. Draw up all 200 µL of the Matrigel mixture
and serially pipette ~25 µL of the mixture into a single well of a 24-well plate.
(viii) Place the plate in the incubator for ~10 min or until Matrigel droplets have solidiﬁed. Add
750 µL of bud tip progenitor organoid complete medium.
(ix) Repeat the needle passage (Step 20B(iii–viii)) every 2–3 weeks, or at any time to select for
the bud tip progenitor population.
(C) Generation and maintenance of bud tip progenitor organoids using bulk passaging
● Timing Epithelium-only cysts will form after ~2 weeks and will contain a nearly
homogeneous population of bud tip progenitor cells. To generate patterned lung
organoids with discrete bud tip and airway-like regions, keep their structure intact during
passaging. Bud tip progenitor organoids that are not needle passaged will develop budded
epithelial structures and elements of proximal–distal patterning, as well as functional
mucus-producing cells on the interior of the structure, after roughly 6 weeks in culture.
c CRITICAL Bud tip progenitor organoids that are not needle passaged will secrete mucus into
the lumen of the organoid, causing a dense appearance and leading to increased cell death;
therefore, these organoids must be cleaned out regularly.
(i) On the day of use, add 50 µg/mL L-ascorbic acid, 0.04 µL/mL monothioglycerol, 10 ng/mL
FGF7, 50 nM ATRA and 3 µM CHIR-99021 to basal medium composed of DMEM/F12 +
N-2 supplement + B27 supplement + 1× L-glutamine + 1× pen–strep to make bud tip
progenitor organoid complete medium (as also detailed in Table 2). Feed foregut spheroids
with 500 µL of bud tip progenitor organoid complete medium.
(ii) Replace media every 3–5 d.
(iii) Passage of bud tip progenitor organoids without a needle. After 2–3 weeks, or sooner if
organoids appear to be accumulating cellular debris within lumens or sinking to the
bottom of the Matrigel droplet, scrape Matrigel droplets containing bud tip progenitor
organoids using a cut P1000 pipette and transfer both the media within the well and the
Matrigel droplet to a Petri dish.
(iv) Use a scalpel to cut away old Matrigel without disturbing the tissue structure, and re-
embed in fresh Matrigel droplets as described in Step 20A(ii–v) above. These organoids
contain bud tip progenitor cells in budded structures at the periphery of the organoid.
Interior regions will predominantly show SOX2+ airway-like structures with differentiated
mucus-producing cells. They can be needle passaged as described in Step 20B(iii–viii) at
any time to select for the bud tip progenitor population.
(v) Clearing mucus from non-needle-passaged organoids. Mucus or cellular debris will often
accumulate within the lumens of organoids and will appear as an optically dense, dark and
granulated substance within the lumen after ~2 weeks in culture without passage. To clear
this debris, get a sterile scalpel, a clean 27-gauge needle, a 1-mL syringe and a fresh aliquot
of prewarmed DMEM/F12. Transfer organoids plus Matrigel to a Petri dish with
prewarmed DMEM/F12 and transfer to a sterile hood with a stereomicroscope.
(vi) Under the stereomicroscope, manually cut organoids in half with the sterile scalpel. Using
the 1-mL syringe with the 27-gauge needle, draw up clean prewarmed DMEM/F12 into the
syringe. Gently expel the media through the needle to wash the mucus away from the
organoids.
● Timing See Fig. 1 for an overview of the timeline of the protocol. Splitting hPSCs to establish the
cell cultures required takes 0.5–1 h (Steps 1–10). The culture reaches appropriate conﬂuency after
1–2 d. The generation of foregut spheroids from hPSCs takes 9 d (Steps 11–14). It takes roughly 1 h
to collect foregut spheroids and culture them in a Matrigel droplet (Steps 15–20). From there,
human lung organoids with airway-like structures and multiple immature epithelial and
mesenchymal cell types can be generated after roughly 50 d in culture (41 d from foregut spheroid
stage; Step 20A(i–v)), whereas bud tip progenitor organoids can be generated within 22 d (14 d from
foregut spheroids stage; Step 20B(i,ii)) and can be maintained as proliferating progenitors (Step 20B
(iii–ix)) or as budded patterned lung organoids with proximal–distal patterning (Step 20C(i–vi)).
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Troubleshooting
The most common problem we have identiﬁed is a failure of foregut spheroids to form during the
directed differentiation of hPSCs (Steps 11–14). Common causes of failure to form spheroids are as
follows: (i) the initial seeding density of hPSCs is too dense; (ii) hPSC colonies are allowed to grow too
large in the 24-well plate; (iii) growth factors were stored at 4 °C for too long and lost potency; and
(iv) hPSC lines were not maintained well (they contained spiky, unhealthy colonies) or differentiation
was started at too high a passage number. Generally, hPSCs with a passage number < 90 should be
used. We have also noticed that high-passage (>70 passages) hPSCs have reduced spheroid-forming
ability. If spheroids fail to form, the experiment must be attempted again from the beginning.
To ensure that the seeding density and colony size of the hPSC starting material are correct, we
recommend comparing results to those shown in Figs. 3h–l and 4b–d. Preliminary and unpublished
experiments in our lab have suggested that stem cells can be broken into colonies as small as single
cells and plated at a density of 125,000 cells per single well of a 24-well plate to generate foregut
spheroids; this could be attempted if mechanical trituration is not working well. Our experience is
that small colonies differentiate far more robustly than large colonies. Review Figs. 3 and 4 as a guide
for appropriate colony sizes.
We also recommend that you record how long growth factors have been stored at 4 °C. When in
doubt, throw them out.
Once spheroids have been plated in Matrigel, another common problem is that the spheroids and
resulting organoids appear to drop to the bottom of the Matrigel droplet and adhere to the plastic
culture dish (Steps 20A(i) and 20B(i)). If this happens, it is crucial to replate the organoids in a fresh
Matrigel droplet as soon as possible; any organoids that have adhered to the plate and have a ‘ﬂat’
morphology should be discarded. Possible reasons for organoids ‘bottoming out’ are that (i) it has
been longer than 2–3 weeks since the last passage, (ii) the Matrigel has been at 4 °C for too long and
the protein concentration has decreased owing to adhesion to the container, or (iii) the Matrigel
droplets were too large and do not have a high dome shape that allows ample room for 3D growth.
Timing
Coating of culture plates: 1.25 h or overnight
Steps 1–10, splitting of hPSC culture: 30–60 min
Steps 11–14, directed differentiation into endoderm and anterior foregut spheroids: 9–12 d: 4 d
deﬁnitive endoderm differentiation, 4–5 d anterior foregut endoderm differentiation
Steps 15–19, collection of ﬂoating anterior foregut spheroids: 15–60 min
Step 20A, generation of human lung organoids: ~50 d
Step 20B, generation of bud tip progenitor organoids by serial needle passaging: ~14–120 d (14 d for
initial growth, 120+ d for maintenance and serial passaging)
Step 20C, generation of budded, patterned lung organoids by bulk passaging: ~6 weeks
Anticipated results
Foregut spheroids should self-aggregate, detach from the monolayer and ﬂoat freely in the media
by the fourth day of foregut differentiation (Fig. 3k–l). The number of spheroids formed in each
well can vary. Generally, a single well will produce roughly 100–400 spheroids by day 5 of
foregut differentiation. They appear as small irregular cell clumps (Fig. 5a) that express NKX2.1 and
SOX2 (Fig. 5b,c).
Human lung organoids
Spheroids that are treated with FGF10 and 1% (vol/vol) FBS will give rise to human lung organoids.
Spheroids grown in these conditions will generate clear epithelial structures by day 12 in culture.
As the organoids grow, mesenchymal populations will be visible surrounding epithelial structures
(Fig. 5d). Epithelial structures will persist until ~100 d in culture, as visualized by H&E staining
(Fig. 5e). By 65 d in culture, human lung organoids will have pseudostratiﬁed epithelial structures
with P63+ basal stem-cell-like cells lining the basal surface (Fig. 5f), as well as a population of cells
with positive staining for the ciliated cell marker FOXJ1 (~5% of all cells; Fig. 5g) and alveolar cell
markers SFTPC and HOPX (~5% of all cells; Fig. 5i,j)15,16. Cells surrounding the epithelial structures
stain positive for multiple mesenchymal cell markers, including smooth muscle actin (Fig. 5g),
PDGFR-α and vimentin (Fig. 5h).
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Bud tip progenitor organoids
For spheroids that are cultured in serum-free medium with FGF7, CHIR99021 and ATRA, by day 12
of culture epithelial structures will form that are positive for SOX2 and NKX2.1 (Fig. 5k,l). To
maintain a highly enriched population of bud tip progenitors, one can needle passage the organoids.
This can be done starting at 2 weeks of culture, or at any time thereafter. Needle-passaged organoids
form round cysts (Fig. 5m), and over 88% of these cells are SOX2+SOX9+ (Fig. 5m)17 and share
similar molecular proﬁles with bud tip progenitors in the human fetal lung before week 16 of
gestation17. If cultures are kept intact and are not broken up, they will form organoids with clear
budded structures by day 45 (Fig. 5n). Epithelial bud tip structures will undergo clear bifurcation
events (Fig. 5o). These ‘patterned lung organoids’ exhibit bud-tip-like and airway-like regions
(Fig. 5p). Interior regions of the organoid contain SOX2+ airway-like cells and mucus-producing
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roughly 2% of cells stain positive for goblet cell marker MUC5AC (Fig. 5q). Bud tip regions of
these organoids will maintain SOX9+, pro–surfactant protein C (ProSFTPC)+ cells, indicating
maintenance of bud tip progenitors (Fig. 5r). Mucus will build up within these organoids, causing the
interior to become dense and optically opaque. Mucus can be cleared during passaging to a fresh
Matrigel droplet.
Reporting Summary
Further information on research design is available in the Nature Research Reporting Summary
linked to this article.
Data availability
Some of the data presented in the current study were generated for and published in previous reports.
Original data used for ﬁgures in this paper are available at the following links: Fig. 2b–d (Dye et al.16),
https://doi.org/10.7554/eLife.19732; Figs. 2e and 5g–j (Dye et al.15), https://doi.org/10.7554/eLife.
05098; Figs. 2g–i and 5l–r (Miller et al.17), https://doi.org/10.1016/j.stemcr.2017.11.012.
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Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency 
in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main 
text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND 
variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Clearly defined error bars 
State explicitly what error bars represent (e.g. SD, SE, CI)
Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection N/A
Data analysis N/A
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers 
upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
Some of the data presented in the current study was generated for and shown in previously published reports. Figure 2 B-D was reproduced with permission from 
Dye et al. 2016 and licensed under CC BY-NC-ND 4.0. The original data can be viewed at https://doi.10.7554/eLife.05098 . Figure 2 E and Figure 5 B-C, G-J were 
reproduced with permission from Dye et al. 2015 and licensed under CC BY-NC-ND 4.0. The original data can be viewed at https://doi.10.7554/eLife.05098 . Figure 2 




G-I and Figure 5 L-R were reproduced with permission from Miller et al. 2018 and licensed under CC BY-NC-ND 4.0. The original data can be viewed at https://
doi.org/10.1016/j.stemcr.2017.11.012 .
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For a reference copy of the document with all sections, see nature.com/authors/policies/ReportingSummary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size Three independent directed differentiation experiments were performed; one using H1 stem cells and two using H9 stem cells. Each directed 
differentiation experiment was performed in a 24 well plate, corresponding to 24 technical replicates per experiment. The purpose of these 
experiments was to document normal experimental progression and cell morphology to aid recapitulation of the protocol. No statistical 
analyses were performed. 
Data exclusions No data were excluded from these analyses.
Replication The experiment was performed in two separate cell lines. The protocol was reproducible in all measured outcomes. Results here were 
consistent with our previously published work.
Randomization Randomization of subjects is not relevant to this study.
Blinding Blinding of researchers to data from this study was not relevant to this work. Three separate experiments were performed for the purpose of 
documenting protocol progression. Results were consistent between these three experiments and with our previously published work.
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Antibodies used Primary Antibody Source Catalog # Dilution 
(Sections) 
Chicken anti-GFP Abcam Ab13970 1:500 
*Biotin-Goat anti-TP63 R&D systems BAF1916 1:500 
*Biotin-Mouse anti MUC5AC Abcam ab79082 1:500 
Goat anti-CC10 (SCGB1A1) Santa Cruz Biotechnology sc-9770 1:200 
Goat anti-Chromogranin A (CHGA) Santa Cruz Biotechnology sc-1488 1:100 
Goat anti-SOX2  Santa Cruz Biotechnology Sc-17320 1:200 
Goat anti-VIMENTIN (VIM) Santa Cruz Biotechnology sc-7558 1:100 
Mouse anti-Acetylated Tubulin (ACTUB) Sigma-Aldrich T7451 1:1000 
Mouse anti-alpha smooth muscle actin (SMA)*Cy3 conjugated Sigma C6198 1:400 
Mouse anti-E-Cadherin (ECAD) BD Transduction Laboratories  610181 1:500 
Mouse anti-FOXJ1 eBioscience 14-9965-82 1:500 
Mouse anti-Human Nuclear Antigen (HuNu) Abcam ab191181 1:250 
Mouse anti-Surfactant Protein B (SFTPB) Seven Hills Bioreagents Wmab-1B9 1:250 
Rabbit anti-HOPX Santa Cruz Biotechnology Sc-30216 1:250 
Rabbit anti-NKX2.1 Abcam ab76013 1:200 
Rabbit anti-Nuclear Mitotic Aparatus – Human (NuMa) Thermo Scientific PA5-22285 1:500 




Rabbit anti-PDGFRalpha Santa Cruz Biotechnology sc-338 1:100 
Rabbit anti-Pro-Surfactant protein C (Pro-SFTPC) Seven Hills Bioreagents Wrab-9337 1:500 
Rabbit anti-SOX9 Millipore AB5535 1:500 
Rabbit anti-Synaptophysin Abcam AB32127 1:500 
    
Secondary Antibody Source Catalog # Dilution 
Donkey anti-goat 488 Jackson Immuno 705-545-147 1:500 
Donkey anti-goat 647 Jackson Immuno 705-605-147 1:500 
Donkey anti-goat Cy3 Jackson Immuno 705-165-147 1:500 
Donkey anti-mouse 488 Jackson Immuno 715-545-150 1:500 
Donkey anti-mouse 647 Jackson Immuno 415-605-350 1:500 
Donkey anti-mouse Cy3 Jackson Immuno 715-165-150 1:500 
Donkey anti-rabbit 488 Jackson Immuno 711-545-152 1:500 
Donkey anti-rabbit 647 Jackson Immuno 711-605-152 1:500 
Donkey anti-rabbit Cy3 Jackson Immuno 711-165-102 1:500 
Donkey anti-goat 488 Jackson Immuno 705-545-147 1:500 
Donkey anti-goat 647 Jackson Immuno 705-605-147 1:500 
Donkey anti-goat Cy3 Jackson Immuno 705-165-147 1:500 
Donkey anti-mouse 488 Jackson Immuno 715-545-150 1:500 
Donkey anti-mouse 647 Jackson Immuno 415-605-350 1:500 
Donkey anti-mouse Cy3 Jackson Immuno 715-165-150 1:500 
Donkey anti-rabbit 488 Jackson Immuno 711-545-152 1:500 
Donkey anti-rabbit 647 Jackson Immuno 711-605-152 1:500 
Donkey anti-rabbit Cy3 Jackson Immuno 711-165-102 1:500 
Streptavidin 488 Jackson Immuno 016-540-084 1:500 
Validation Antibody validation was performed by the manufacturer. 
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) hESC lines H9 and H1 (NIH registry #0062 and #0043, respectively) were obtained from the WiCell Research Institute.
Authentication Cell lines are routinely karotyped to ensure no genetic transformations have occurred. 
Mycoplasma contamination All cell lines tested negative for Mycoplasma contamination.
Commonly misidentified lines
(See ICLAC register)
Name any commonly misidentified cell lines used in the study and provide a rationale for their use.
